Bayer and Dachen Pharma have successfully completed the first year of their collaborative MOVE-on-Site (MoS) initiative, achieving notable advancements in sustainability and operational efficiency. The program, launched in May 2023, has led to significant reductions in carbon emissions and improved economic performance for Dachen Pharma, marking a key milestone in their shared journey towards sustainable development.

 The MoS initiative, spearheaded by Bayer's global AIM-OE team, has focused on refining Dachen Pharma’s production and operational systems. Through a series of in-depth discussions between Bayer’s senior experts and Dachen Pharma’s teams across production, research and development, and quality control, the companies have worked to optimize manufacturing processes and identify areas for improvement.

Central to the initiative is the question: "Can we do better?" This proactive approach has allowed both teams to establish and pursue clear improvement targets and action plans. As milestones were reached, the strategy was continuously refined, leading to measurable gains in product quality, transparency in production losses, cost reductions, and enhanced overall efficiency.

The MoS initiative has fostered greater collaboration between Dachen Pharma’s production teams and various departments, leading to improved skill development and problem-solving capabilities. Bayer’s external perspective has played a crucial role in deepening Dachen Pharma’s understanding of its processes, building confidence, and reinforcing the trust between the two companies.

Looking forward, Dachen Pharma plans to continue applying MoS principles to further enhance its product processes and competitiveness in the market. Both companies remain committed to driving sustainable development, with the MoS initiative serving as a key catalyst for future economic growth and industry-wide benefits.

This partnership underscores Bayer and Dachen Pharma’s shared vision for long-term sustainability and mutual success.